Altman Peter 4

What Happened
Peter Altman, President, CEO and a director of BioCardia, acquired a total of 900 shares in open-market purchases: 600 shares on Jan 20, 2026 at an average reported price of $1.32 ($792) and 300 shares on Jan 21, 2026 at an average reported price of $1.34 ($402). These were purchases (not sales), representing insider buying activity.

Key Details

• Transaction dates and reported averages:
  • 2026-01-20: 600 shares at $1.32 avg (executed in multiple trades $1.31–$1.33) — $792
  • 2026-01-21: 300 shares at $1.34 avg (executed in multiple trades $1.34–$1.35) — $402
• Total acquired: 900 shares for approximately $1,194.
• Shares owned after the transactions: not disclosed in the provided filing excerpt.
• Footnotes: reporting person notes both transactions were executed in multiple trades and provided weighted-average prices; full per-trade details are available upon request to the SEC/issuer (footnotes F1 and F2).
• Filing timeliness: Form 4 filed 2026-01-21 for trades on Jan 20–21 — appears filed promptly (not indicated as late).

Context
These were open-market purchases (code P), a direct cash purchase of shares. The total dollar amount is modest, so while insider buying can be viewed positively, the purchase size here is small relative to typical institutional or company-scale activity; retail investors should consider this as one data point and review broader fundamentals and disclosures.